These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33826105)

  • 1. Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu H; Wang Z; Wang Y; Yu J; Fan Y; Li Y; Wang J; Cao G; Guo B; Chen Y; Liu X; Bian X; Wu J; Li H; Wu X; Zhang J
    Infect Dis Ther; 2021 Jun; 10(2):911-923. PubMed ID: 33826105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal AnaerobicInfection.
    Wu H; Xie S; Yu J; Chen Y; Wu J; Guo B; Zhu Z; Zhou Y; Wang Z; Zhang J
    Clin Ther; 2018 Sep; 40(9):1548-1555. PubMed ID: 30146271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis.
    Guo B; He G; Wu X; Yu J; Cao G; Li Y; Fan Y; Chen Y; Shi Y; Zhang Y; Zhang J
    Clin Ther; 2017 Jul; 39(7):1336-1346. PubMed ID: 28619503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis.
    Cao Y; Li Y; Guo B; Zhang J; Wu X; Yu J; Cao G; Fan Y; Wu H
    Int J Antimicrob Agents; 2023 Apr; 61(4):106754. PubMed ID: 36773938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis.
    Hu J; Zhang J; Chen Y; Liang W; Wu S
    Clin Ther; 2017 Apr; 39(4):828-836. PubMed ID: 28363695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis.
    Wu J; Yang X; Wu J; Wang J; Wu H; Wang Y; Yuan H; Yang H; Wang H; Zhang J
    Front Pharmacol; 2023; 14():1135007. PubMed ID: 36992830
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
    Wu X; Li Y; Zhang J; Zhang Y; Yu J; Cao G; Chen Y; Guo B; Shi Y; Huang J; Cao Y; Liu X; Wu J; Gordeev MF; Yuan H; Wang W
    Clin Ther; 2018 Feb; 40(2):322-332.e5. PubMed ID: 29398160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of Single-Dose Amphotericin B Colloidal Dispersion in Healthy Chinese Subjects and Population Pharmacokinetic/Pharmacodynamic Analysis to Inform Clinical Efficacy in Invasive Infections Caused by Candida albicans.
    Huang ZW; Yu JC; Wang JJ; Chen YC; Wu JF; Chen YJ; Cao GY; Yang HJ; He JJ; Dai JY; Zhang JY; Zhang W; Yuan J; Li CL; Xu FY; Wang K; Wu XJ; Zhang J
    Clin Ther; 2021 Nov; 43(11):1921-1933.e7. PubMed ID: 34686365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of injected ornidazole compared to its enantiomer levornidazole in healthy Chinese subjects.
    Liu Y; Zhang Y; Xue W; Wang J; Bai W; Wang T; Liu Y; Tang K; Qin J; Li K; Wang X
    Int J Clin Pharmacol Ther; 2023 Dec; 61(12):543-550. PubMed ID: 37840522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of YK-1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Li Y; Yan B; Guo S; Tian M; Li Y; Tong H; Yu Y; Shao J; Xin Y; Chen H; Xu B; Li X
    Br J Clin Pharmacol; 2023 Oct; 89(10):3067-3078. PubMed ID: 37255194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved pharmacokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers.
    Cao Y; Wu X; Chen Y; Guo B; Yu J; Cao G; Zhang J; Shi Y; Zhang Y
    Int J Antimicrob Agents; 2016 Mar; 47(3):224-8. PubMed ID: 26920104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.
    Cao G; Zhang J; Wu X; Yu J; Chen Y; Ye X; Zhu D; Zhang Y; Guo B; Shi Y
    J Clin Pharm Ther; 2013 Oct; 38(5):394-400. PubMed ID: 23701411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects.
    Hu Y; Wei Q; Bian X; Yang X; Yu J; Wang J; Yang H; Cao G; Wu X; Zhang J
    Antibiotics (Basel); 2023 Aug; 12(9):. PubMed ID: 37760689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
    Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
    J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.